<DOC>
	<DOC>NCT02007837</DOC>
	<brief_summary>Hypertensive disorders of pregnancy (HDP) are with 50.000 deaths every year one of the major causes of maternal mortality worldwide, especially in low and middle income countries. This trial aims to determine whether a daily dose of combined low-dose aspirin, calcium, vitamin D3, folic acid and vitamin B12 in pregnancy reduces the incidence of pregnancy-induced hypertension in women at risk. Secondary and tertiary objectives include other maternal and neonatal outcomes.</brief_summary>
	<brief_title>Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>&lt;16 weeks of gestation and over 18 years of age, Intention to have subsequent antenatal visits and delivery at the same clinic. Can receive text messages by phone or through the phone of a proxy. A moderate to high risk (&gt;20%) of developing PIH Preexisting hypertension or hypertension before 20 weeks gestation. Likely noncompliance with the protocol in view of the treating physician Comorbidity interfering with the protocol Known contraindications to Investigational Product components</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pregnancy induced hypertension</keyword>
	<keyword>gestational hypertension</keyword>
	<keyword>pre-eclampsia</keyword>
	<keyword>preeclampsia</keyword>
	<keyword>hypertensive disorders in pregnancy</keyword>
</DOC>